Compare J M Smucker Co (SJM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs State Street SPDR S&P Biotech ETF — how do they compare? J M Smucker Co trades at $119.83 (market cap $12.76B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.75% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SJM | XBI | |
|---|---|---|
Market Cap | $12.76B | $10.11B |
Volume | 1,300,545 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $132.34 | $169.55 |
52-Week Low | $89.53 | $104.99 |
Typical Hold Time | 74 Days | 38 Days |
Enterprise Value | $19.61B | — |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM stock trades at $119.41, up 3.0% with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The company maintains strong cash flow from operations at $1.21B and recently raised FY27 EPS guidance to $10.50-$11.00. However, 2025 results showed a net loss of $1.23B despite $8.73B revenue, with elevated P/E ratio of 55.8 suggesting premium valuation.
Outlook remains cautiously optimistic with analyst consensus target of $138.23 (16% upside) and 52% buy ratings, though high debt levels and margin pressures present risks. The stock offers dividend income with upcoming $1.12 payment, while technical support at $118 provides near-term stability.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
